Sutent Cleared For Pancreatic Tumors, But With Caveat On Efficacy

FDA approves Pfizer's sunitinib with labeling that states the magnitude of progression-free survival benefit seen in the pivotal study may have been overestimated due to the trial's early termination.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet